Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 1,870,000 shares, an increase of 26.4% from the February 13th total of 1,480,000 shares. Based on an average daily trading volume, of 299,700 shares, the short-interest ratio is currently 6.2 days. Approximately 2.4% of the company's shares are sold short.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on CRDL shares. Rodman & Renshaw initiated coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $7.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Monday, February 24th. Finally, RODMAN&RENSHAW raised Cardiol Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $8.40.
Read Our Latest Stock Report on CRDL
Cardiol Therapeutics Stock Up 5.4 %
Shares of CRDL stock traded up $0.06 on Wednesday, hitting $1.18. 203,752 shares of the stock were exchanged, compared to its average volume of 389,045. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $97.48 million, a P/E ratio of -3.03 and a beta of 0.95. Cardiol Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $3.12. The business has a 50-day moving average of $1.25 and a 200 day moving average of $1.58.
Institutional Investors Weigh In On Cardiol Therapeutics
Institutional investors have recently bought and sold shares of the company. Townsquare Capital LLC acquired a new stake in shares of Cardiol Therapeutics in the third quarter valued at approximately $27,000. Jane Street Group LLC bought a new position in Cardiol Therapeutics in the third quarter valued at $29,000. Lion Street Advisors LLC increased its stake in Cardiol Therapeutics by 12.6% in the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock valued at $396,000 after buying an additional 34,385 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at $25,000. Finally, Atria Investments Inc bought a new stake in Cardiol Therapeutics during the 4th quarter worth about $174,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.